Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Apr 27;81(4):1029-1035.
doi: 10.1021/acs.jnatprod.8b00062. Epub 2018 Apr 19.

Absolute Configuration and Pharmacology of the Poison Frog Alkaloid Phantasmidine

Affiliations

Absolute Configuration and Pharmacology of the Poison Frog Alkaloid Phantasmidine

Richard W Fitch et al. J Nat Prod. .

Abstract

Phantasmidine, a rigid congener of the well-known nicotinic acetylcholine receptor agonist epibatidine, is found in the same species of poison frog ( Epipedobates anthonyi). Natural phantasmidine was found to be a 4:1 scalemic mixture, enriched in the (2a R,4a S,9a S) enantiomer by chiral-phase LC-MS comparison to the synthetic enantiomers whose absolute configurations were previously established by Mosher's amide analysis. The major enantiomer has the opposite S configuration at the benzylic carbon to natural epibatidine, whose benzylic carbon is R. Pharmacological characterization of the synthetic racemate and separated enantiomers established that phantasmidine is ∼10-fold less potent than epibatidine, but ∼100-fold more potent than nicotine in most receptors tested. Unlike epibatidine, phantasmidine is sharply enantioselective in its activity and the major natural enantiomer whose benzylic carbon has the 4a S configuration is more active. The stereoselective pharmacology of phantasmidine is ascribed to its rigid and asymmetric shape as compared to the nearly symmetric conformations previously suggested for epibatidine enantiomers. While phantasmidine itself is too toxic for direct therapeutic use, we believe it is a useful platform for the development of potent and selective nicotinic agonists, which may have value as pharmacological tools.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosure

Indiana State University and NIH jointly hold a patent on phantasmidine derivatives (Fitch, R. W; Spande, T. F.; Garraffo, H. H.; Yeh, H. J. C.; Daly, J. W. Nicotinic Receptor Agonists, US 20130281482 A1 and subsequent issuances). Brandeis University holds a patent on the synthesis of phantasmidine derivatives (Snider, B. B.; Zhou, Q. Preparation of Phantasmidine and Analogues Thereof, WO 2012078608 A1).

Figures

Figure 1.
Figure 1.
Chiral-phase LC-MS chromatograms showing extracted ions for phantasmidine (1), epibatidine (2a) and N-methylepibatidine (2b) in E. anthonyi extract. All ions are shown in the top trace. Ions in the mass range indicated on the right are shown in subsequent traces.
Figure 2.
Figure 2.
Functional profiles of phantasmidine as the racemate (top panel) and individual enantiomers (bottom panels) at rat nicotinic and serotonin receptor-expressing Xenopus oocytes.
Figure 3.
Figure 3.
Molecular Electrostatic Potential Maps of Epibatidine, Phantasmidine, Varenicline and Cytisine.

References

    1. Daly JW; Spande TF; Garraffo HM J. Nat. Prod 2005, 68, 1556–1575. - PubMed
    1. Fitch RW; Spande TF; Garraffo HM; Yeh HJC; Daly JW J. Nat. Prod 2010, 73, 331–337. - PMC - PubMed
    1. Spande TF; Garraffo HM; Edwards MW; Yeh HJC ; Pannell L; Daly JW J. Am. Chem. Soc 1992, 114, 3475–3478.
    1. Badio B; Daly JW Mol. Pharmacol 1994, 45, 563–569. - PubMed
    1. Badio B; Garraffo HM; Spande TF; Daly JW Med. Chem. Res 1994, 4, 440–448.

Publication types

MeSH terms

LinkOut - more resources